Humana Inc. (NYSE:HUM) Shares Sold by CIBC Asset Management Inc

CIBC Asset Management Inc trimmed its holdings in Humana Inc. (NYSE:HUM) by 11.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,481 shares of the insurance provider’s stock after selling 2,101 shares during the quarter. CIBC Asset Management Inc’s holdings in Humana were worth $6,158,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HUM. CarsonAllaria Wealth Management Ltd. increased its stake in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares during the period. Private Wealth Management Group LLC acquired a new position in Humana in the 4th quarter valued at $32,000. Hantz Financial Services Inc. acquired a new position in Humana in the 2nd quarter valued at $35,000. Family Firm Inc. acquired a new position in Humana in the 2nd quarter valued at $37,000. Finally, Riverview Trust Co acquired a new position in Humana in the 2nd quarter valued at $44,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HUM has been the topic of several recent research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price objective on shares of Humana in a research note on Monday, August 19th. Bank of America boosted their target price on shares of Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a research report on Monday, May 20th. Truist Financial boosted their target price on shares of Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, July 15th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research report on Friday, August 2nd. Finally, TD Cowen boosted their target price on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Thirteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Humana has an average rating of “Hold” and an average price target of $396.35.

Humana Price Performance

Humana stock opened at $371.40 on Thursday. Humana Inc. has a 52 week low of $298.61 and a 52 week high of $530.54. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $367.95 and its 200 day simple moving average is $347.21. The firm has a market capitalization of $44.75 billion, a PE ratio of 23.13, a P/E/G ratio of 3.16 and a beta of 0.51.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $8.94 EPS. On average, equities research analysts predict that Humana Inc. will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a yield of 0.95%. Humana’s dividend payout ratio (DPR) is 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.